157 related articles for article (PubMed ID: 12226017)
1. Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness.
Langley SJ; Holden J; Derham A; Hedgeland P; Sharma RK; Woodcock A
Chest; 2002 Sep; 122(3):806-11. PubMed ID: 12226017
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
Ayres JG; Millar AB; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM
Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
Perruchoud AP; Lundback B; Yigla M; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684
[TBL] [Abstract][Full Text] [Related]
6. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma.
Lee DK; Haggart K; Currie GP; Bates CE; Lipworth BJ
Br J Clin Pharmacol; 2004 Jul; 58(1):26-33. PubMed ID: 15206989
[TBL] [Abstract][Full Text] [Related]
7. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma.
Lee DK; Fardon TC; Bates CE; Haggart K; McFarlane LC; Lipworth BJ
Chest; 2005 Mar; 127(3):851-60. PubMed ID: 15764767
[TBL] [Abstract][Full Text] [Related]
8. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma.
Currie GP; Fowler SJ; Wilson AM; Sims EJ; Orr LC; Lipworth BJ
Thorax; 2002 Oct; 57(10):865-8. PubMed ID: 12324672
[TBL] [Abstract][Full Text] [Related]
9. Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children.
Lyttle B; Gilles J; Panov M; Emeryk A; Wixon C
Can Respir J; 2003 Mar; 10(2):103-9. PubMed ID: 12687029
[TBL] [Abstract][Full Text] [Related]
10. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
Fowler SJ; Currie GP; Lipworth BJ
J Allergy Clin Immunol; 2002 Jun; 109(6):929-35. PubMed ID: 12063520
[TBL] [Abstract][Full Text] [Related]
11. The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction.
Giannini D; Di Franco A; Bacci E; Dente FL; Taccola M; Vagaggini B; Paggiaro P
Chest; 2000 May; 117(5):1319-23. PubMed ID: 10807817
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate.
Fowler SJ; Orr LC; Sims EJ; Wilson AM; Currie GP; McFarlane L; Lipworth BJ
Chest; 2002 Aug; 122(2):618-23. PubMed ID: 12171841
[TBL] [Abstract][Full Text] [Related]
13. Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma.
Pinnas JL; Noonan MJ; Weinstein SF; Chervinsky P; Scott CA; Herje NE; Wu W; Crim C
J Asthma; 2005 Dec; 42(10):865-71. PubMed ID: 16393726
[TBL] [Abstract][Full Text] [Related]
14. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.
Lumry WR; Conway MM; LaForce CF; Pearlman DS; Scott CA; Herje NE; Wu WW; Crim C
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):51-9. PubMed ID: 16440533
[TBL] [Abstract][Full Text] [Related]
15. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.
Kunka R; Andrews S; Pimazzoni M; Callejas S; Ziviani L; Squassante L; Daley-Yates PT
Respir Med; 2000 Jun; 94 Suppl B():S10-6. PubMed ID: 10919680
[TBL] [Abstract][Full Text] [Related]
16. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant.
Mackie AE; McDowall JE; Ventresca P; Bye A; Falcoz C; Daley-Yates PT
Clin Pharmacokinet; 2000; 39 Suppl 1():17-22. PubMed ID: 11140429
[TBL] [Abstract][Full Text] [Related]
17. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[TBL] [Abstract][Full Text] [Related]
18. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant.
Woodcock A; Williams A; Batty L; Masterson C; Rossetti A; Cantini L
J Aerosol Med; 2002; 15(4):407-14. PubMed ID: 12581507
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler.
Dempsey OJ; Wilson AM; Coutie WJ; Lipworth BJ
Chest; 1999 Oct; 116(4):935-40. PubMed ID: 10531156
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
